March 1, 2007 – Amgen revealed it is under an informal SEC investigation for not publicly disclosing Aranesp side effects; Point Therapeutics said its cancer drug failed a Phase II test; Dynavax began a Phase I trial of its hepatitis B vaccine; Sunesis asked for permission to begin a Phase I trial of a cancer drug; Adherex completed the purchase of all of the GlaxoSmithKline options for eniluracil, a potential cancer drug; BioSante published results of its pivotal trial of Elestrin, an estradiol gel; Wyeth received a recommendation for approval of its vaccine Prevenar in Europe; Alnylam and Isis received a patent for microRNAs and therapeutic products that target these miRNAs; Cytogen said the NCI began a Phase II trial of Quadramet; Dendreon reported an FDA advisory panel will review Provenge, a cancer immunotherapy, on March 29; OncoGenex increased the number of shares being offered in its IPO and lowered the price; and Sirtis and Helicos both filed for their IPOs. The Centient Biotech 200™ fell 66 points to 3864, a loss of 1.67%. More details...
